ESSA Pharma (EPIX) Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research cut shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) from a buy rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
Several other research analysts also recently weighed in on EPIX. HC Wainwright started coverage on shares of ESSA Pharma in a report on Monday, March 26th. They set a buy rating and a $0.70 price objective on the stock. ValuEngine upgraded shares of ESSA Pharma from a strong sell rating to a sell rating in a report on Friday, February 2nd. Finally, Bloom Burton upgraded shares of ESSA Pharma from a hold rating to a buy rating in a report on Thursday, January 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $0.48.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Tuesday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter. equities analysts forecast that ESSA Pharma will post -1.73 earnings per share for the current year.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.